Evox Therapeutics Enters into Agreement to Advance Next-Generation Exosome-Delivered AAV Gene Therapy for Treatment of Heart Disease; Evox Will Team with Dr. Susmita Sahoo, Icahn School of Medicine

On August 4, 2023, Evox Therapeutics Ltd, a leading exosome therapeutics company, announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY. The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Together, Evox and Icahn Mount Sinai are focused on tackling a long-standing challenge in cardiovascular medicine, namely the safe and effective delivery of genetic medicines to cardiomyocytes. By enhancing the precision of gene delivery to heart muscle cells and cleverly evading the immune response, this novel exoAAV technology has the potential to redefine the use of gene therapy in the cardiovascular disease field. Susmita Sahoo, PhD, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai has been exploring the use of exosomes in gene therapy for a number of years and her group’s latest findings were published in the the August 1, 2023 issue of the renowned cardiovascular disease journal Circulation. The open-access article is titled “Extracellular Vesicle–Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart.” The agreement between Evox and Icahn Mount Sinai builds on this initial phase of work by combining Evox’s leading exosome technology know-how and capabilities with Icahn Mount Sinai’s deep understanding of gene delivery and expertise in cardiovascular research and clinical translation.
Login Or Register To Read Full Story